Rigel Pharmaceuticals (RIGL) PT Raised to $7 at Cantor Fitzgerald, Following Strategic Business Update
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Cantor Fitzgerald analyst Kristen Kluska raised the price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $7.00 (from $5.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aphria Inc. (APHA:CN) (APHA) PT Raised to Cdn$30 at Cantor Fitzgerald
- Babcock International Group Plc (BAB:LN) (BCKIF) PT Raised to GBP2.60 at Morgan Stanley
- ESR Cayman Ltd (1821:HK) (ESRCF) PT Raised to HK$29.20 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesCantor Fitzgerald
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!